Author Listing of Relationships With Industry and Other Entities (Comprehensive)—2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure (July 2019)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Donald E. Casey, Jr, Chair	Thomas Jefferson College of Population Health—Adjunct Faculty; Rush Medical College— Faculty; University of Minnesota, Institute of Health Informatics— Affiliate Faculty; President, American College of Medical Quality; IPO 4 Health—Principal and Founder	• NCQA†	None	None	None	• ACMQ†	None
Randal J. Thomas, Vice Chair	Mayo Clinic—Medical Director, Cardiac Rehabilitation Program	None	None	None	None	None	None
Vivek Bhalla	Stanford University Medical Center—Assistant Professor of Medicine, Nephrology; Stanford Hypertension Center—Director	CareDx ClearView Healthcare Partners Cogentia Maxim Integrated Relypsa, Inc. Strafluence	None	None	None	 Oraxion Therapeutics PyrAmes Health† 	• Plaintiff, delayed disclosure of chronic kidney disease for patient with hypertension, 2017*
Yvonne Commodore- Mensah	Johns Hopkins School of Nursing—Assistant Professor	None	None	None	None	None	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Paul A. Heidenreich	Stanford VA Palo Alto Health Care System—Professor of Medicine	None	None	None	Bracco Diagnostics	None	None
Dhaval Kolte	Massachusetts General Hospital and Harvard Medical School— International Cardiology Fellow	None	None	None	None	None	None
Paul Muntner	University of Alabama at Birmingham—Professor, Department of Epidemiology	Amgen Inc.National Center for Health Statistics*	None	None	• AHA* • Amgen Inc.* • NIH*	None	None
Sidney C. Smith, Jr	University of North Carolina at Chapel Hill—Professor of Medicine; Division of Cardiology, Department of Medicine	None	None	None	None	None	None
John A. Spertus	Washington University School of Medicine in St. Louis—Adjunct Professor of Medicine, Cardiovascular Division; Saint Luke's Mid America Heart Institute—Director, Health Outcomes Research; University of Missouri-Kansas City—Professor, Daniel J. Lauer Missouri Endowed Chair in Metabolism and Vascular Disease Research	 AstraZeneca* Bayer Healthcare Pharmaceuticals Boehringer Ingelheim* Janssen* Merck Sharp & Dohme Corporation* Novartis* Regeneron Pharmaceuticals, Inc.* SAQ, KCCQ, and PAQ* 	• Abbott	• Health Outcomes Sciences*	• ACC*	• ACC Foundation* • AHA† • AstraZeneca UK Limited • Blue Cross Blue Shield of Kansas City* • CV Outcomes† • Novartis*	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
		 United Healthcare Scientific Advisory Board 					
John R. Windle	University of Nebraska College of Medicine—Professor, Internal Medicine, Division of Cardiovascular Medicine	• IBM Watson	None	None	 Agency for Healthcare Research and Quality* Pew Charitable Trust 	• WebMD*	None
Gregory D. Wozniak	American Medical Association— Director, Outcomes Analytics; Northwestern University, Feinberg School of Medicine— Adjunct Assistant Professor	None	None	None	None	• AHRQ† • NACHC/CDC†	None
Boback Ziaeian	UCLA David Geffen School of Medicine—Assistant Professor; US Department of Veterans Affairs—Assistant Professor	• AHA	None	None	• ACC • AHA*	• AHA*	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq 5\%$,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for WCs.

ACC indicates American College of Cardiology; ACMQ, American College of Medical Quality; AHA, American Heart Association; NIH, National Institutes of Health; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.

^{*}Significant relationship.

[†]No financial benefit.